Woojung Bio announced on the 24th that it signed an industry-academic cooperation agreement with Dongguk University College of Pharmacy on the 23rd to jointly research and develop new drugs, establish an open innovation support system, and promote mutual development through human and technological exchanges.
Through this agreement, both institutions plan to promote ▲ joint research and development of new drugs and collaboration on non-clinical trials ▲ execution of joint research projects ▲ early discovery of promising research or commercializable ideas ▲ establishment of various open innovation support systems ▲ cooperation in pharmaceutical practical training and talent development ▲ exchange of research personnel and information.
With this agreement, Woojung Bio aims to secure excellent technologies proactively through technology commercialization and incubating infrastructure provision, as well as industry-academic joint research, while actively cooperating to cultivate entrepreneurial capabilities of talented individuals and secure outstanding personnel with mid- to long-term goals.
Cheon Byeong-nyeon, CEO of Woojung Bio, stated, “Through this agreement, we expect to expand the infrastructure of Woojung Bio’s new drug cluster, an open innovation platform, and to grow the contract research organization (CRO) business for non-clinical trials. By conducting joint projects, we aim to discover excellent technologies early and integrate them into our services, establish a virtuous cycle structure that secures outstanding talent early through talent development support, and maximize the strengths of both institutions through startup support and investment.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
